This article has been updated to include a statement from UpScriptHealth. In August 2024, Pfizer Inc (NYSE:PFE) introduced ...

JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. Now, a study designed to prove its safety ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

The market sentiment in the next few months is likely to be quite positive for Pfizer. Read why I maintain my strong buy ...

tofacitinib (Xeljanz, Pfizer) 5 mg twice per day and upadacitinib (Rinvoq, Abbvie) 15 mg daily. The meta-analysis ultimately included nine randomized controlled trials representing a total of ...

Despite a drop in legacy product sales like Xeljanz, Pfizer demonstrated resilience through effective cost management. Notably, Pfizer's R&D expenditure rose by 8% operationally, reinforcing its ...

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific O ...

Higher-priced drugs, including Vyndaqel, Ibrance, Xtandi and Xeljanz, are expected to be most affected by the IRA. Pfizer expects Comirnaty and Paxlovid to maintain market share in 2025 with ...